Alzheimer's disease: Where next for anti-amyloid therapies?

Brain

Volumn 140, Issue 4, 2017, Pages 853-855

  Hardy, John ^a   De Strooper, Bart ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID; AMYLOID PROTEIN;

ALZHEIMER DISEASE; DISEASE COURSE; EDITORIAL; HUMAN; NONHUMAN; PRIORITY JOURNAL; AMYLOIDOSIS; IMMUNOTHERAPY; METABOLISM; PHYSIOLOGY; PROCEDURES;

ALZHEIMER DISEASE; AMYLOID; AMYLOID BETA-PEPTIDES; AMYLOIDOGENIC PROTEINS; AMYLOIDOSIS; HUMANS; IMMUNOTHERAPY;

EID: 85028552628     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awx059     Document Type: Editorial

References (18)

1. De Strooper B, Karran E. The cellular phase of Alzheimer's disease. Cell 2016; 164: 603-15.
2. De Strooper B, Voet T Alzheimer's disease: a protective mutation. Nature 2012; 488: 38-9.
3. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM. Peripheral anti-Abeta antibody alters CNS and plasma Abeta clearance and decreases brain Abeta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2001; 98: 8850-5.
4. Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med 2014; 370: 311-21.
5. Escott-Price V, Sims R, Bannister C, Harold D, Vronskaya M, Majounie E, et al. Common polygenic variation enhances risk prediction for Alzheimer's disease. Brain 2015; 138 (Pt 12): 3673-84.
6. Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, et al. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008; 372: 216-23.
7. Hyde L, Chen X, Stahl L, Sondey M, Scott J, Cumming J, et al. Chronic BACE inhibition dramatically slows the rate of Aß accumulation and the development of amyloid plaques in young TgCRND8 mice. Alzheimers Dement 2012: 8: 188.
8. Jack CR Jr, Holtzman DM. Biomarker modeling of Alzheimer's disease. Neuron 2013; 80: 1347-58.
9. Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson PV, Bjornsson S, et al. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 2012; 488: 96-9.
10. Karran E, Hardy J. A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease. Ann Neurol 2014; 76: 185-205.
11. Karran E, Mercken M, De Strooper B. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov 2011; 10: 698-712.
12. Kennedy ME, Stamford AW, Chen X, Cox K, Cumming JN, Dockendorf MF, et al. The BACE1 inhibitor verubecestat (MK-8931) reduces CNS b-amyloid in animal models and in Alzheimer's disease patients. Sci Transl Med 2016; 8: 363ra150.
13. Matarin M, Salih DA, Yasvoina M, Cummings DM, Guelfi S, Liu W, et al. A genome-wide gene-expression analysis and database in transgenic mice during development of amyloid or tau pathology. Cell Rep 2015; 10: 633-44.
14. Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med 2016; 8: 595-608.
15. Sevigny J, Chiao P, Bussière T, Weinreb PH, Williams L, Maier M, et al. The antibody aducanumab reduces Ab plaques in Alzheimer's disease. Nature 2016; 537: 50-6.
16. Siemers ES, Sundell KL, Carlson C, Case M, Sethuraman G, Liu-Seiferta H, et al. Phase 3 solanezumab trials: secondary outcomes in mild Alzheimer's disease patients. Alzheimers Dement 2016; 12: 110-20.
17. Small SA, Duff K. Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis. Neuron 2008; 60: 534-42.
18. Walker LC, Diamond MI, Duff KE, Hyman BT. Mechanisms of protein seeding in neurodegenerative diseases. JAMA Neurol 2013; 70: 304-10.